Bayer's $66B Monsanto buy spells bad news for its pharma ambitions: Analysts

Bayer sign

Bayer’s longtime target Monsanto has finally agreed to join hands with a $66 billion transaction. But what does the deal mean for the German drugmaker’s pharma ambitions? Nothing good, analysts say.

The tie-up, announced Wednesday, is a “lost opportunity to develop the pharma pipeline,” Bernstein’s Ronny Gal wrote in late July, noting that “Bayer does not have the funds to invest in both Ag and Pharma at the same time”--and it doesn’t have the time to wait before making more pharma investments, either.

The damage won’t happen overnight, as powerhouse meds Eylea, an eye treatment, and Xarelto, a next-gen anticoagulant, should keep sales growing  “well into 2020,” Gal predicts. But Bayer doesn’t have up-and-coming candidates to replace blockbuster-selling Xarelto once it loses patent protection in 2024, and now would be the time to start bringing in assets to do just that.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

BMI Research’s Craig Smith echoed similar concerns earlier in the year, pointing out that the Leverkeusen-based company already spends less than its Big Pharma peers do on R&D. With that in mind, “this deal could significantly weaken” Bayer’s “capacity to grow within the pharmaceuticals space,” in particular hampering the in-need consumer health unit.

That business segment was supposed to get a boost from Bayer’s last big acquisition, its 2014 pickup of Merck’s ($MRK) OTC division. The deal was designed to aid Bayer’s quest to snatch the No. 1 worldwide position in consumer health. But Q2 showcased “weakness” that Gal found “concerning ... particularly given the integration is now complete.”

Bayer acknowledges that its healthcare division, which includes pharma, consumer healthcare, and animal health, will shrink in importance. The healthcare group represented almost 70% of the company's sales in 2015, while pro forma numbers for the post-merger company show it will amount to 49% going forward.

Critics of the Monsanto ($MON) needn’t worry just yet, though. It might not come to fruition. “We expect fairly major political hurdles for a deal to pass EU and U.S. regulators,” Gal’s colleague, Jonas Oxgaard, wrote in a note earlier this month, putting the merger’s chance of success at 50%.

But of course, even for those rooting against a deal close, there’s a downside to a failed tie-up. “Bayer may spend a year spinning its wheels trying to win regulatory approval, which may not be coming,” Gal wrote.

- read Bayer's deal release

Related Articles:
Bayer eyes $1B-plus dermatology sale to fund Monsanto quest
Bayer's desired Monsanto buy could hurt its pharma, OTC ambitions: Analyst
Bayer's interest in Monsanto reignites talk of animal health sale
Ambitious Bayer puts up $27B sales goal for 2017, with OTC carrying a big load
Bayer aims to crush consumer health rivals with $14B Merck unit buyout


Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.